179 related articles for article (PubMed ID: 38396173)
1. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
[TBL] [Abstract][Full Text] [Related]
2. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID).
Crabb SJ; Griffiths G; Marwood E; Dunkley D; Downs N; Martin K; Light M; Northey J; Wilding S; Whitehead A; Shaw E; Birtle AJ; Bahl A; Elliott T; Westbury C; Sundar S; Robinson A; Jagdev S; Kumar S; Rooney C; Salinas-Souza C; Stephens C; Khoo V; Jones RJ
J Clin Oncol; 2021 Jan; 39(3):190-201. PubMed ID: 33326257
[TBL] [Abstract][Full Text] [Related]
3. Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
Crabb SJ; Griffiths G; Dunkley D; Downs N; Ellis M; Radford M; Light M; Northey J; Whitehead A; Wilding S; Birtle AJ; Khoo V; Jones RJ
Eur Urol; 2022 Nov; 82(5):512-515. PubMed ID: 35688662
[TBL] [Abstract][Full Text] [Related]
4. PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.
Feron M; Guevel L; Rouger K; Dubreil L; Arnaud MC; Ledevin M; Megeney LA; Cherel Y; Sakanyan V
Am J Pathol; 2009 Apr; 174(4):1459-70. PubMed ID: 19264909
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
6. O2-(2,4-dinitrophenyl) diazeniumdiolate derivative induces G2/M arrest via PTEN-mediated inhibition of PI3K/Akt pathway in hepatocellular carcinoma cells.
Liu L; Xu J; Zhai Z; Cao M; Huang Z; Xing Y; Chen J
J Pharm Pharmacol; 2021 Sep; 73(10):1330-1339. PubMed ID: 34190329
[TBL] [Abstract][Full Text] [Related]
7. FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
Ma L; He H; Jiang K; Jiang P; He H; Feng S; Chen K; Shao J; Deng G
Aging (Albany NY); 2020 Apr; 12(7):6352-6369. PubMed ID: 32283544
[TBL] [Abstract][Full Text] [Related]
8. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky MP; Rescigno P; Bianchini D; Zafeiriou Z; Mehra N; Mateo J; Michalarea V; Riisnaes R; Crespo M; Figueiredo I; Miranda S; Nava Rodrigues D; Flohr P; Tunariu N; Banerji U; Ruddle R; Sharp A; Welti J; Lambros M; Carreira S; Raynaud FI; Swales KE; Plymate S; Luo J; Tovey H; Porta N; Slade R; Leonard L; Hall E; de Bono JS
Ann Oncol; 2020 May; 31(5):619-625. PubMed ID: 32205016
[TBL] [Abstract][Full Text] [Related]
9. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
10. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
12. PTEN, Akt, and GSK3beta signalling in rat primary cortical neuronal cultures following tumor necrosis factor-alpha and trans-4-hydroxy-2-nonenal treatments.
Rickle A; Behbahani H; Ankarcrona M; Winblad B; Cowburn RF
J Neurosci Res; 2006 Aug; 84(3):596-605. PubMed ID: 16802321
[TBL] [Abstract][Full Text] [Related]
13. Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.
Dixon KM; Lui GY; Kovacevic Z; Zhang D; Yao M; Chen Z; Dong Q; Assinder SJ; Richardson DR
Br J Cancer; 2013 Feb; 108(2):409-19. PubMed ID: 23287991
[TBL] [Abstract][Full Text] [Related]
14. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
15. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer.
Gao C; Yuan X; Jiang Z; Gan D; Ding L; Sun Y; Zhou J; Xu L; Liu Y; Wang G
Breast Cancer Res Treat; 2019 Jul; 176(2):291-301. PubMed ID: 31006103
[TBL] [Abstract][Full Text] [Related]
16. PP9, a steroidal saponin, induces G2/M arrest and apoptosis in human colorectal cancer cells by inhibiting the PI3K/Akt/GSK3β pathway.
Yao M; Li R; Yang Z; Ding Y; Zhang W; Li W; Liu M; Zhao C; Wang Y; Tang H; Wang J; Wen A
Chem Biol Interact; 2020 Nov; 331():109246. PubMed ID: 32877639
[TBL] [Abstract][Full Text] [Related]
17. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
Beckham TH; Cheng JC; Lu P; Marrison ST; Norris JS; Liu X
PLoS One; 2013; 8(10):e76593. PubMed ID: 24098536
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Nomura T; Yamasaki M; Hirai K; Inoue T; Sato R; Matsuura K; Moriyama M; Sato F; Mimata H
Mol Cancer; 2013 Apr; 12():27. PubMed ID: 23566222
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Sharma M; Chuang WW; Sun Z
J Biol Chem; 2002 Aug; 277(34):30935-41. PubMed ID: 12063252
[TBL] [Abstract][Full Text] [Related]
20. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
